Track record · closed signal

Innoviva Inc. (INVA) — closed signal from May 8, 2026

Partial Published before the outcome was known, scored automatically when the window closed on August 6, 2026 — -8.1% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$22.00 – $23.30Entry zone — fair-value band

$22.97Published — price the day we called it

$27.10Target — the price the thesis aimed for

$24.17Peak — highest point inside the window, not a realized return

$21.11Window close — end-of-window price, context only

What happened

Partial

Reached 29% of the predicted growth at its peak, without hitting the target.

At window close

-8.1%

realized, from the publication price to the last close inside the window

Peak gain

+5.2%

peak, from the publication price — not a realized return

S&P 500, same window

+4.5%

SPY over the identical days, dividend-adjusted

Window close

$21.11

last close inside the window, ended August 6, 2026

Peak price

$24.17

peak on June 24, 2026 — not a realized return

Days to target

—

The thesis — published May 8, 2026

Predicted growth

+18%

over the measurement window

Target price

$27.10

the price the thesis aimed for

Entry zone

$22.00 – $23.30

the fair-value band we waited for

Price at publication

$22.97

published May 8, 2026

Confidence

78%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Innoviva looks like a cheaper healthcare company with stronger-than-usual profit margins and a track record of delivering earnings. It also has cash on the balance sheet that helps limit downside risk. The short-term concern is that recent news is broad industry context rather than company-specific, and the stock is oversold until selling pressure eases.

Primary drivers

Low price relative to fundamentals helps limit losses
Royalties and product income generate high profit margins
Recent reported results have generally been positive
Cash on hand reduces financial risk for the company

How it played out

INVA: the 18% thesis didn't play out

Lyra published INVA at $22.97 with an expected gain of 18% and a $27.10 target. The thesis pointed to a low price relative to fundamentals, high margins from royalties and product income, generally positive reported results, and cash on hand that reduced financial risk.

The stock peaked at $24.17 on June 24, a gain of 5.2%. It stayed below the target throughout the window and ended at $21.11 on August 6. The early rise was limited and did not hold. The published thesis missed.

What happened during the window

On June 16, Innoviva said its subsidiary entered a distribution and licensing agreement with Dr. Reddy's for XACDURO in selected international markets. On August 5, the company reported second-quarter results, including $59.8 million in royalty revenue and $36.6 million in U.S. net product sales.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals